drugset / Trial / NCT00577460
Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The general aim of this study is to obtain long-term safety and tolerability data on pramipexole extended release (ER), in daily doses from 0.375mg to 4.5mg once daily (qd), in patients who have previously completed a pramipexole double-blind study in advanced Parkinson's disease (PD) (248.525 trial).
Timeline
- Start
- 2007-12
- Primary completion
- 2010-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pramipexole | Unknown | 0.375 mg | — |
| Comparator | Pramipexole | Unknown | 4.5 mg | — |